Skip to main content
Consun Pharmaceutical Group Limited logo

Consun Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1681 ISIN · KYG2524A1031 LEI · 300300LQFLNDZZHCNN43 HKEX Manufacturing
Open in API
Filings indexed 852 across all filing types
Latest filing 2026-05-22 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1681

About Consun Pharmaceutical Group Limited

http://www.chinaconsun.com

Consun Pharmaceutical Group Limited is a modern pharmaceutical enterprise engaged in the integrated research, development, manufacturing, and marketing of pharmaceutical products. The company's core business is segmented into Modern Chinese Medicines (MCM) and Medical Contrast Medium products. The MCM portfolio targets major therapeutic areas, including chronic renal diseases (featuring products like Uremic Clearance Granules), liver and gallbladder conditions, and orthopedic trauma. In the medical imaging field, Consun supplies contrast agents such as Gadopentetate Dimeglumine Injection for magnetic resonance imaging (MRI) and Iopamidol Injection for angiography and neuro-radiology. The enterprise focuses on combining the modernization of Chinese medicine with advanced diagnostic solutions.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return (Form FF305) filed with the Hong Kong Stock Exchange detailing the issuer’s share repurchases, treasury share changes, and on‐market transactions in its own shares, including quantities, prices, dates, and confirmations under the Listing Rules. This is a report of transactions in the company’s own shares, matching the definition of 'Transaction in Own Shares' (Code: POS).
2026-05-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is an HKEX Next Day Disclosure Return (Form FF305) detailing actual changes in issued shares and treasury shares, specifically the repurchase of 102,000 shares as treasury shares and related confirmations. It is a direct report of a share buyback transaction (transaction in own shares), not a broader financial report or simple announcement. Therefore it falls under Transaction in Own Shares (POS).
2026-05-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 88% confidence The document is a Form FF305 “Next Day Disclosure Return” filed under Hong Kong Listing Rules detailing changes in issued shares and treasury shares, specifically including share repurchase data (dates, volumes, prices) and confirmations required by Exchange rules. This is a report of the company buying back its own shares (transaction in own shares), matching the POS category.
2026-05-20 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing (Form FF301) submitted to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Consun Pharmaceutical Group Limited for the month ended 30 April 2026. It details movements in authorized share capital, issued shares, treasury shares, share options, and public float sufficiency confirmation. The document is regulatory in nature, providing compliance confirmations and share capital movements, but it does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, earnings release, or investor presentation. It is also not a report publication announcement or certification letter. The document fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement related to share capital and compliance with listing rules under HKEX.
2026-05-04 English
2025 Environmental, Social and Governance Report
Regulatory Filings
2026-04-28 English
ANNUAL REPORT 2025
Annual Report Classification · 100% confidence The document is titled '2025 Annual Report' and contains detailed sections typical of a full annual report, including Chairman's Statement, Financial Highlights, Management Discussion and Analysis, Directors and Senior Management Profile, Corporate Governance Report, Report of Directors, Independent Auditor's Report, and comprehensive financial statements such as Consolidated Statement of Profit or Loss, Statement of Financial Position, and Notes to the Financial Statements. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement. The content includes audited consolidated results for the year ended 31 December 2025, detailed business performance, and financial data. This matches the definition of an Annual Report (10-K).
2026-04-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.